company background image
MDP

Medexus Pharmaceuticals TSX:MDP Stock Report

Last Price

CA$2.90

Market Cap

CA$57.9m

7D

-3.3%

1Y

11.1%

Updated

17 Aug, 2022

Data

Company Financials +
MDP fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance2/6
Financial Health0/6
Dividends0/6

MDP Stock Overview

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States.

Medexus Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Medexus Pharmaceuticals
Historical stock prices
Current Share PriceCA$2.90
52 Week HighCA$4.58
52 Week LowCA$1.59
Beta1.12
1 Month Change58.47%
3 Month Change10.69%
1 Year Change11.11%
3 Year Change-27.32%
5 Year Change-35.56%
Change since IPO-61.33%

Recent News & Updates

Shareholder Returns

MDPCA PharmaceuticalsCA Market
7D-3.3%5.6%3.2%
1Y11.1%-61.8%2.1%

Return vs Industry: MDP exceeded the Canadian Pharmaceuticals industry which returned -61.8% over the past year.

Return vs Market: MDP exceeded the Canadian Market which returned 2.1% over the past year.

Price Volatility

Is MDP's price volatile compared to industry and market?
MDP volatility
MDP Average Weekly Movement10.4%
Pharmaceuticals Industry Average Movement13.6%
Market Average Movement10.6%
10% most volatile stocks in CA Market18.9%
10% least volatile stocks in CA Market4.3%

Stable Share Price: MDP is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: MDP's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a100Ken d'Entremonthttps://www.medexus.com

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company’s primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication.

Medexus Pharmaceuticals Inc. Fundamentals Summary

How do Medexus Pharmaceuticals's earnings and revenue compare to its market cap?
MDP fundamental statistics
Market CapCA$57.87m
Earnings (TTM)CA$2.99m
Revenue (TTM)CA$106.59m

19.4x

P/E Ratio

0.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MDP income statement (TTM)
RevenueUS$82.48m
Cost of RevenueUS$32.79m
Gross ProfitUS$49.69m
Other ExpensesUS$47.38m
EarningsUS$2.31m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.12
Gross Margin60.24%
Net Profit Margin2.80%
Debt/Equity Ratio323.3%

How did MDP perform over the long term?

See historical performance and comparison